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Background. Treatment of fetal pancreas (FP) 
isografts with insulin-like growth factor-I greatly im-
proves the rate of conversion to euglycemia in diabetic 
rats. Complete knowledge of other factors that may 
facilitate the engraftment and function of FP in vivo is 
still embryonic. Augmenter of liver regeneration 
(ALR) is a newly described polypeptide growth factor 
found in weanling rat livers. ALR has trophic effects 
on regenerating liver. We studied the effects of in situ 
administration of this agent on FP isografts in rats. 
Methods. Streptozotocin-diabetic Lewis rats (blood 
glucose >300 mg/dl) received 16 FP isografts trans-
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planted intramuscularly. ALR was delivered from day 1 
through day 14, in doses of 40 or 400 ng/kg/d. Animals 
were followed for 3 months with serial weights and 
blood glucose monitoring. These animals were com-
pared with those treated with vehicle alone. 
Results. Of the group treated with ALR at 40 ng/kg/ 
day for 14 days, 89% (eight of nine) were euglycemic 
(P=0.0003). Of the group treated with ALR at 400 ng/ 
kg/day for 14 days, 88% (seven of eight) were euglyce-
mic (P=O.OOO7). Of the group treated with vehicle 
alone, none of the six were euglycemic. Euglycemia is 
defined here as glucose<200 mg/dl for 3 days. Pathol-
ogy of the intramuscular transplant site showed 
patches of islet tissue embedded in fat. These patches 
demonstrated insulin immunoreactivity. 
Conclusions. Diabetes was reversed in a significantly 
greater proportion of FP + ALR-treated recipients than 
those animals treated with vehicle alone. Local delivery of 
growth factors may be used as an adjunct to FP transplan-
tation to improve the rate of success. This in situ model 
may be useful to further evaluate other soluble factors. 
Because of its generative capacity, transplantation of fetal 
pancreatic (FP*) tissue is an attractive approach to the treat-
* Abbreviations: ALR, augmenter of liver regeneration; FP, fetal 
pancreas; IGF-I, insulin-like growth factor-I. 
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ment of diabetes mellitus (1-3). Human FP grafts have been 
shown to undergo selective endocrine differentiation and to 
correct diabetes in athymic mice (4, 5). Human FP allograft 
transplantation has been attempted, but only transient func-
tion of the grafts has been documented (6). These results 
demonstrate that there is incomplete understanding of the 
various factors necessary for engraftment, growth, matura-
tion, and function of FP grafts. 
Augmenter of liver regeneration (ALR) is a newly de-
scribed polypeptide growth factor found in the cytosol of 
weanling rat livers (7). Its mechanism of action is still un-
clear. It has a trophic effect on liver regeneration after hep-
atectomy, and it augments proliferation in experimental ca-
nine portocaval shunt models (8). It has no effect on resting 
livers in vivo, nor does it increase thymidine incorporation in 
hepatocyte cultures in vitro. Experiments were designed to 
evaluate the effects of ALR, alone or in combination with 
insulin-like growth factor-I (IGF-I), on fetal isografts. 
MATERIALS AND METHODS 
Animals. Inbred Lewis rats were obtained from Harlan Bioprod-
ucts for Science \Indianapolis, IN) and were allowed free access to 
standard rat chow and water. Animal care was administered in 
accordance with the policies of the Institutional Animal Care and 
Use Committee at Stanford University Medical Center. 
Induction of diabetes. Diabetes was induced in all recipients with 
a single intravenous injection of streptozotocin (100 mg/kg, Zanosar, 
Upjohn Co., Kalamazoo, MI). Each graft recipient had at least two 
serial blood glucose determinations greater than 350 mg/dl before 
transplantation. Before and after transplantation, diabetic rats re-
ceived long-acting insulin protamine zinc insulin (NPH Ilentin, Eli 
Lilly, Indianapolis, IN) in doses of 2-8 units every other day, de-
pending on random blood glucose determinations to prevent weight 
loss and facilitate FP growth (9). Exogenous insulin was not admin-
istered if blood glucose was less than 250 mg/d1. 
Surgical technique for intramuscular implantation of FP. Accord-
ing to the technique of Wang et a1. (10), 20-21-day gestational pups 
were isolated by cesarean section from time-pregnant Lewis rats 
under anesthesia using isoflurane (AErrane, Anaquest Inc., Liberty 
Corner, NJ) through a vaporizing system (Omni Medical Equipment, 
Inc., Pleasanton, CAl. FPs were removed by blunt dissection. FPs 
were minced into I-mm" pieces and washed twice in Hanks' balanced 
salt solution. Tissues were kept on ice in Hanks' balanced salt solu-
tion until transplantation. Mter sterile preparation of male Lewis 
recipients (150-250 gl, an incision was made over the anterior sur-
face of each hind leg and a l-cm pocket created in the underlying 
muscle. Grafts of 8 or 16 FP were divided equally between the two 
pockets. The grafts were covered by approximation of the muscle, 
and the skin closed with surgical clips. Growth factors were delivered 
directly into the transplant bed by osmotic minipumps (Alza Corp., 
Palo Alto, CAl placed in an anterior abdominal subcutaneous space. 
A polyethylene catheter (PE 50, Clay Adams, Parsippany, NJ) lead-
ing from the pump to the bed was secured in place with suture. ALR 
(kindly supplied by T.E. Starz!) was delivered in doses of 40 or 400 
ng/kg/day for 14 days. IGF-I (recombinant human IGF-I; kind gift of 
Genentech, San Francisco, CAl was delivered in doses of 69 ILg/kgl 
day for 14 days. Animals receiving FP grafts and treated with vehicle 
alone served as controls. Pumps were removed on day 15 after 
transplantation and bisected to confirm complete drug delivery. 
Blood glucose determination. Mter transplantation, blood glucose 
determinations were made by tail vein bleedings three times a week 
using an Ames Glucofilm system (Miles, Elkhart, IN). Reversal of 
diabetes was defined as blood sugars less than 200 mg/dl on three 
consecutive measurements. 
Glucose tolerance testing. Glucose tolerance tests were performed 
on transplanted rats that had converted to euglycemia. Dextrose was 
diluted to 500 mg/kg in normal saline and administered by intrave-
nous injection. Blood glucose determinations were made before dex-
trose injection and at 5-, 15-, 30-, 60-, and I20-min intervals there-
after. 
Histology. Mter fixation in 10% neutralized formalin, sections 
were stained with hematoxylin and eosin. Insulin immunoreactivity 
was demonstrated with mouse anti-human insulin monoclonal anti-
body (E54071 M, Biodesign International, Kennebunkport, ME) on 
6-lLm paraffin-embedded sections using a commercially available kit 
(Histostain-DS Broad Spectrum, Zymed Labs, Inc., South San Fran-
cisco, CAl. 
Data analysis. Results are reported only on those animals that 
reverted to hyperglycemia after graft removal and had no histologi-
cal evidence of islets remaining in the native pancreas. Categorical 
differences were analyzed by Fisher's exact probability test, and 
interval differences by analysis of variance. A P-value of less than 
0.05 was considered significant. 
RESULTS 
Treatment ofFP isografts with ALR significantly increased 
the rate of conversion to euglycemia when compared with 
vehicle alone. This was true of both doses tested. Adminis-
tration of 40 ng/kg/day increased the conversion rate to 89% 
(eight of nine) with an interval of 76 ::+: 54 days from trans-
plant to conversion. Administration of 400 ng/kg/day had 
similar results with a conversion rate of 88% (seven of eight) 
and an interval of61 ::+: 11 days. None of the animals treated 
with vehicle alone converted to euglycemia. See Table l. 
Reducing the mass of transplanted FP resulted in a one-
third decrease in the efficiency in the rate of conversion. 
When eight FP isografts were treated with 40 ng of ALRJkg/ 
day for 14 days, 62% (five of eight) of the rats converted with 
a mean interval of 51 ::+: 17 days. See Table 2. As reported 
previously (14), IGF-I administered at a rate of 69 J.Lg/kg/day 
resulted in a conversion rate of 89% (eight of nine) with a 
mean interval of 57 ::+: 27 days (14). Combination of ALR with 
IGF-I did not offer an advantage over either agent alone. 
Animals receiving eight FP grafts and treated with 40 ng of 
ALRJkg/day plus 69 J.Lg ofIGF-IIkg/day converted at a rate of 
83% (five of six) with a mean interval of 63 ::+: 14 days 
(P=0.114). 
Figure 1 shows the typical blood glucose trends in a single 
ALR-treated rat after transplant. Random blood glucose lev-
els in normal rats averaged 111 ::+: 7 mg/dl by tail vein 
bleeding. Streptozotocin-treated rats were consistently above 
300 mg/dl. All animals receiving FP isografts at day 0 re-
mained hyperglycemic during the 14-day treatment period 
during which ALR was administered. For 1-2 weeks before 
conversion to euglycemia, the glucose levels began to fluctu-
ate. Once conversion had occurred, blood glucose levels re-
TABLE 1. Effects of two doses of ALR treatment on 16 fetal 
pancreatic isografts transplanted into the intramuscular site 
Groupb FP % EuglycemicC Intervald pe 
40 
400 
Vehicle 
16 
16 
16 
89 (8/9) 
88 (7/8) 
0(0/6) 
76 (::+::54) 
61(::+::11) 
0.0003 
0.0007 
a % Euglycemia is listed as percent of animals cured (animals 
curedlsample size). 
b Concentration of ALR in ng/kg/day, delivered for 14 days. 
c Glucose <200 mgldl x 3 days (# curedl# total). 
d Mean interval (::+::SD) transplant to euglycemia in days. 
e Fishers exact test compared to untreated controls. 
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TABLE 2. Success rates of engTaftment of 8 fetal pancreas isografts 
in the intramuscular site following treatment with ALR, IGF-I, or 
ALR plus IGF-I 
Group 
ALR 40b 
IGF 69c 
IGF/ALR 
FP 
8 
8 
8 
% Euglycemic 
62 (518) 
89 (7/9) 
83 (5/6) 
Interval 
51 (:!: 17) 
57 ( :!: 27) 
63 (± 14) 
" % Euglycemia is lis ted as percent of animals cured (animals 
cured/sample size). 
b Concentration of ALR in ng/kg/day, delivered for 14 days. 
C Concentration of IGF in /Lglkg/day, delivered for 14 days. 
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FIGURE l. Glucose measurements over time in a FP recipient 
treated with ALR at 40 ng/kg/day. 
mained normal until the grafts were removed from the in-
tramuscular site, at which time serum glucose levels 
returned to the diabetic range. 
Intravenous glucose tolerance tests were performed on all 
euglycemic animals at more than 100 days after transplant. 
Averaged results of those data are shown in Figure 2. Glu-
cose tolerance tests of the ALR-treated isograft recipients 
were not significantly different from those from normal rats 
(P=0.12 by analysis of variance). 
Histological analysis of the excised intramuscular grafts 
from euglycemic animals routinely showed islet tissue im-
bedded in fat (Fig. 3, top). Immunohistochemical staining 
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FIGURE 2. Similar mean results of glucose tolerance tests comparing 
rats treated with ALR at 40 nglkg/day and 400 ng/kg/day to normal 
nondiabetic rats. The graph represents clearance of sugar from the 
blood stream after a glucose challenge. 
showed insulin reactivity in {3 cell granules (Fig. 3, bottom). 
Histology of the native pancreas after streptozotocin treat-
ment revealed a paucity of islets and an atrophic appearance 
to those identified. Those islets present lacked insulin reac-
tivity by immunohistochemistry. 
DISCUSSION 
Currently, only vascularized whole pancreas grafts are 
routinely used clinically. These grafts may achieve near-
euglycemia (11). Usually, however, the recipients already 
have end-stage diabetic nephropathy, which requires a si-
multaneous kidney transplant. In this setting, the one year 
pancreas graft survival has improved steadily. However, 
there is still significant morbidity and mortality associated 
with this procedure (12). 
Results of the clinical transplantation of isolated adult 
islets have been disappointing (13). Insufficient yield of is-
lets, impure preparations, lack of engraftment, and rejection 
continue to frustrate efforts. 
The goal ofFP transplantation is to introduce a functional 
islet cell mass into patients with type 1 diabetes mellitus. 
This tissue is expected to achieve the physiological glucose 
control thought necessary for the prevention, retardation , or 
reversal of diabetic neurovascular complications. The advan-
tages of FP include availability, proliferative capacity, and 
viability after preservation. Allografts of human FP have 
FIGURE 3. (Top) Hematoxylin-eosin stained FP graft tissue excised 
from the intramuscular site (original magnification, X50). (Bottom) 
Insulin immunoreactivity in the FP graft tissue (original magnifica-
tion, X50). 
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been transplanted into various sites including intramuscu-
larly and under the capsule of a kidney, with only transient 
C-peptide production (6). However, a better understanding of 
well-defined growth factors and the production of these 
growth factors by recombinant technology offer the opportu-
nity to re-evaluate FP transplantation. 
We have reported that diabetes may be reversed in rats 
receiving FP allografts and treated with IGF-I (14). We also 
found that treatment of grafts with anti-IGF-I receptor anti-
body increased the interval to conversion in the successful 
FP/fetalliver co-transplantation model (15). Administration 
of IGF-I to cultured adult rat islets or to neonatal rat pan-
creatic monolayers has been shown to increase insulin secre-
tion and {3 cell replication (16, 17). It is likely that other 
mediators elaborated by liver may have trophic effects on FP. 
An incomplete list of growth factors that may playa role in 
this experimental system includes the cytosolic pancreatic 
factor ilotropin (18) and hepatocyte growth factor (19), in 
addition to IGF-I and -II (20). 
The choice of ALR was based on its trophic effects on liver 
despite its lack of mitogenic stimulation. Initially, it was 
believed that ALR may be synergistic with IGF -I with respect 
to the IGF-I effects on FP. 
Our evidence shows that local delivery of ALR or IGF-I to 
FP isografts transplanted intramuscularly improves the suc-
cess rate of correction of streptozotocin-induced diabetes in 
rats. Milligram for milligram, ALR may be roughly 100 times 
more potent than IGF-I with respect to its effects on FP, 
based on the concentrations chosen here. Once conversion to 
euglycemia occurred, the animals remained euglycemic until 
such time as the grafts were surgically removed. Combina-
tion of ALR and IGF-I was not synergistic, nor did it ad-
versely affect the conversion rate. In all cured FP recipients 
that were treated with ALR, glucose clearance to challenge 
was normalized. 
The precise mechanism(s) of the beneficial effects of ALR 
in this model is unknown. ALR is found mainly in platelets 
and in germ cell lines and does not have tight homology to 
other known peptide growth factors. The closest homology is 
to bifunctional gene in the yeast Saccharomyces cerevisiae, 
which is responsible for oxidative phosphorylation and veg-
etative growth. This suggests a very primitive role for ALR in 
growth functions. The yeast gene is a regulator of gene ex-
pression related to growth and is not a direct growth factor. 
The ALR-induced increase in hepatic regeneration after he-
patic resection suggests a role in liver growth or repair, 
although ALR does not appear to directly increase DNA 
synthesis in the resting hepatocyte in vitro. This argues for 
an indirect role, either via stimulation of other mitogenic 
agents or by reversal of those factors that may restrict or 
inhibit hepatocyte growth. 
The direct effect of ALR on FP is worthy of further study. 
ALR is no longer being administered to the graft bed by the 
time the pancreas reaches a critical mass and glucose levels 
begin to normalize. But the trend toward euglycemia is ap-
parent in Figure 1 by the second week after treatment. It is 
interesting to note that there was no overcompensation; the 
glucose levels after conversion were in the same range as 
normal rats. 
To optimize FP transplantation as an approach to the 
treatment of diabetes, we need to define better the role that 
growth factors play, in particular, IGF-I and ALR, in the 
maturation of FP grafts. Our current studies demonstrate 
that IGF-I increases the frequency of successful transplan-
tation, and decreases the amount of tissue required for suc-
cessful FP transplantation. ALR also has positive effects in 
this system. Similar strategies incorporating the paracrine 
support of engrafting islets may improve the previously poor 
results of clinical fetal islet transplantation. 
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